Seelos Therapeutics, Inc.

Equities

SEEL

US81577F2083

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
0.2424 ^USD	-11.89%		-17.58%	-82.56%

May. 14	Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	MT
Apr. 29	Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	CI

Seelos Therapeutics, Inc. Announces Executive Changes

January 24, 2019 at 08:01 am EST

Seelos Therapeutics, Inc. announced the completion of its previously disclosed merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics, Inc. Raj Mehra, Ph.D., Chairman, founder and CEO of Seelos will serve as the Chairman, CEO and President of the combined company, and Richard Pascoe, the former CEO of Apricus, will serve on the Board of Directors. Other board members include: Robin L. Smith, M.D., Chairman of the Board of The Stem for Life Foundation; Daniel J. O'Connor, CEO of OncoSec Medical, Inc.; and Brian Lian, Ph.D., CEO and President of Viking Therapeutics, Inc.

Latest news about Seelos Therapeutics, Inc.

Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	May. 14	MT
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	Apr. 29	CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	Mar. 19	MT
Seelos Therapeutics' ALS treatment fails in mid-stage study	Mar. 19	RE
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	Mar. 19	CI
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	Mar. 04	MT
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	Mar. 03	MT
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	Jan. 26	MT
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	Jan. 22	CI
Certain Warrants of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Certain Stock Options of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Certain Common Stock of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	Dec. 19	MT
Seelos Therapeutics Files $250 Million Mixed Shelf	Dec. 19	MT
Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from S&P Global BMI Index	Dec. 18	CI
Seelos Therapeutics Insider Bought Shares Worth $100,223, According to a Recent SEC Filing	Dec. 01	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	Nov. 29	MT
Sector Update: Health Care	Nov. 29	MT
Top Midday Decliners	Nov. 29	MT
Top Premarket Decliners	Nov. 29	MT
Seelos Therapeutics Prices Common Stock Offering	Nov. 29	MT
Seelos Therapeutics Commences Common Stock Offering	Nov. 28	MT
Seelos Therapeutics, Inc. Announces the Selection of SLS-002 (intranasal Racemic Ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder	Nov. 27	CI
Top Decliners	Nov. 24	MT

Chart Seelos Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
SEELOS THERAPEUTICS, INC.	-82.56%	3.32M
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	106B
BIONTECH SE	-12.56%	22.24B
ARGENX SE	-3.44%	21.25B
GENMAB A/S	-5.80%	18.97B
WUXI APPTEC CO., LTD.	-35.21%	18.52B
BEIGENE, LTD.	-10.86%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.54B
LEGEND BIOTECH CORPORATION	-26.24%	8.09B

Bio Therapeutic Drugs